Joseph A. Sparano

ORCID: 0000-0002-9031-2010

Also affiliated with Icahn School of Medicine at Mount Sinai

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 58 papers. Top paper: “Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx”.

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

Journal of Clinical Oncology(2020)10.1200/jco.19.01866

N/A

3.5DataRank · unranked

102 citations

Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina R. Yanez +14 more

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial

Journal of Clinical Oncology(2023)10.1200/jco.23.00377

N/A

2.3DataRank · unranked

46 citations

Fengmin Zhao, Ju‐Whei Lee, Edward H. Ip, John Devin Peipert, Noah Graham +11 more

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Blood(2020)10.1182/blood.2019003959

N/A

2.1DataRank · unranked

70 citations

Joseph A. Sparano, Amy Chadburn, Erin Reid, Richard F. Ambinder, Eric R. Siegel +13 more

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.24.00526

N/A

0.442DataRank · unranked

11 citations

Fengmin Zhao, Tarah J. Ballinger, Sofia F. Garcia, Fei Shen, Shamsuddin Virani +19 more

Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma

Haematologica(2020)10.3324/haematol.2019.243386

N/A

0.425DataRank · unranked

16 citations

Jeannette Y. Lee, Lawrence D. Kaplan, Juan Carlos Ramos, Richard F. Ambinder, William Wachsman +8 more

Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study

The Oncologist(2022)10.1093/oncolo/oyac004

N/A

0.317DataRank · unranked

5 citations

Page C. Moore, Milan Bimali, Timothy P. Cooley, Joseph A. Sparano, Michelle A. Rudek +7 more

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

Cancer(2021)10.1002/cncr.33992

N/A

0.266DataRank · unranked

4 citations

Santiago Saldana, Kathy D. Miller, Ruth C. Carlos, Ilana F. Gareen, Joseph A. Sparano +9 more

MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Radiology(2025)10.1148/radiol.241628

N/A

0.216DataRank · unranked

3 citations

Ruya Kang, Anum S. Kazerouni, Debosmita Biswas, Vivian Belenky, Rhea Chitalia +18 more

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

Cancer(2024)10.1002/cncr.35187

N/A

0.208DataRank · unranked

3 citations

Fengmin Zhao, Ingrid A. Mayer, Amyé Tevaarwerk, Sofia F. Garcia, Carlos L. Arteaga +20 more

CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07519-z

N/A

0.174DataRank · unranked

2 citations

Anne O’Neill, Bryan P. Schneider, Todd C. Skaar, Minetta C. Liu, Caroline Lohrisch +9 more

Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7004

N/A

0DataRank · unranked

1 citations

Robert J. Gray, Joseph A. Sparano, Ruth C. Carlos, Gelareh Sadigh, Sofia F. Garcia +6 more

Breast cancer patients’ insurance status correlates with their adherence to endocrine therapy: Analysis of ECOG-ACRIN TAILORx trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7041

N/A

0DataRank · unranked

0 citations

Robert J. Gray, Betina R. Yanez, Lynne I. Wagner, Sofia F. Garcia, Joseph A. Sparano +3 more

Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Radiology(2021)10.1148/radiol.2021204743

N/A

0DataRank · unranked

38 citations

Justin Romanoff, Constance D. Lehman, Seema A. Khan, Ruth C. Carlos, Sunil Badve +17 more

Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial

Cancer(2021)10.1002/cncr.33527

N/A

0DataRank · unranked

29 citations

Robert J. Gray, Joseph A. Sparano, Betina R. Yanez, Sofia F. Garcia, Lava Timsina +5 more

Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.29697

N/A

0DataRank · unranked

15 citations

Bradley S. Snyder, Ilana F. Gareen, Constance D. Lehman, Seema A. Khan, Justin Romanoff +7 more

Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy

Cancer(2021)10.1002/cncr.33939

N/A

0DataRank · unranked

5 citations

Robert J. Gray, Joseph A. Sparano, Amyé Tevaarwerk, Ruth C. Carlos, Betina R. Yanez +6 more

Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study

BMJ Open(2021)10.1136/bmjopen-2021-053397

N/A

0DataRank · unranked

4 citations

Mindy Ginsberg, Yihong Wang, Fergus J. Couch, Heather Spencer Feigelson, Robert T. Greenlee +9 more

Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Radiology(2021)10.1148/radiol.2021219016

N/A

0DataRank · unranked

5 citations

Justin Romanoff, Constance D. Lehman, Seema A. Khan, Ruth C. Carlos, Sunil Badve +17 more

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.605

N/A

0DataRank · unranked

7 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +12 more

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.520

N/A

0DataRank · unranked

2 citations

Anne O’Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff +3 more

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12003

N/A

0DataRank · unranked

2 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

Reply to T. Shimoi et al and Y. Shimanuki et al

Journal of Clinical Oncology(2021)10.1200/jco.21.01905

N/A

0DataRank · unranked

2 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +20 more

Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6564

N/A

0DataRank · unranked

0 citations

Bradley S. Snyder, Ilana F. Gareen, Constance D. Lehman, Seema A. Khan, Justin Romanoff +14 more

A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e12507

N/A

0DataRank · unranked

0 citations

Joseph A. Sparano, Young Chandler, Claudine Isaacs, Allison W. Kurian, Lawrence H. Kushi +4 more

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer

npj Breast Cancer(2022)10.1038/s41523-021-00376-9

N/A

0DataRank · unranked

27 citations

Anne O’Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff +3 more

Racial disparity in distant recurrence‐free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials

Cancer(2022)10.1002/cncr.34241

N/A

0DataRank · unranked

25 citations

Jessica Pastoriza, Jiyue Qin, Juan Lin, George S. Karagiannis, John S. Condeelis +9 more

Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer

Cancer(2022)10.1002/cncr.34426

N/A

0DataRank · unranked

15 citations

Malin Hovstadius, Melanie Wain Kier, Erin Moshier, Brittney S. Zimmerman, Krystal Cascetta +4 more

Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL

Scientific Reports(2022)10.1038/s41598-022-13101-8

N/A

0DataRank · unranked

14 citations

Shelly Lensing, Di Chang, Larry Magpantay, Ronald T. Mitsuyasu, Richard F. Ambinder +4 more

Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy

npj Breast Cancer(2022)10.1038/s41523-022-00463-5

N/A

0DataRank · unranked

8 citations

Anthony Bianchi, Luis Rivera Sanchez, Kamal Ambadipudi, Min‐Hui Cui, Jesús Anampa +16 more

Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12094

N/A

0DataRank · unranked

0 citations

John Devin Peipert, Vered Stearns, Victor T. Chang, Opeyemi A. Jegede, Edward H. Ip +15 more

The MLL3/TP53/PIK3CA cancer driver mutations promote HIF1α-dependent recruitment and differentiation of pro-tumor ICOS hi GITR hi Blimp-1 + effector regulatory T cells in breast tumors

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.02.510540

N/A

0DataRank · unranked

0 citations

Kenta Nishitani, Piril Erler, Nicole Couturier, Zheng Zhang, Anna Maria Militello +9 more

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

The Lancet(2023)10.1016/s0140-6736(23)00285-4

N/A

0DataRank · unranked

195 citations

Rosie Bradley, Richard Gray, Robert K. Hills, Hongchao Pan, Richárd Pető +95 more

Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy

npj Breast Cancer(2023)10.1038/s41523-023-00547-w

N/A

0DataRank · unranked

23 citations

Burcu Karadal-Ferrena, Jiyue Qin, Ved P. Sharma, Isabelle Oktay, Yu Lin +14 more

Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study

Cancer(2023)10.1002/cncr.35110

N/A

0DataRank · unranked

18 citations

Chia-Ching J. Wang, Himanshu Joshi, Shelly Lensing, Jeannette Y. Lee, Juan Carlos Ramos +14 more

Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer

npj Breast Cancer(2023)10.1038/s41523-023-00591-6

N/A

0DataRank · unranked

12 citations

Julia White, Sandra M. Swain, Eileen Rakovitch, Reshma Jagsi, Timothy J. Whelan +2 more

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7045

N/A

0DataRank · unranked

10 citations

Helga S. Marques, Gloria Xue, Richard L. Hoffman, Constantine Gatsonis, Fengmin Zhao +4 more

Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1142

N/A

0DataRank · unranked

3 citations

Jeannette Y. Lee, Elizabeth Y. Chiao, David M. Aboulafia, Lee Ratner, Richard F. Ambinder +6 more

Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study

npj Breast Cancer(2024)10.1038/s41523-024-00622-w

N/A

0DataRank · unranked

13 citations

Robert J. Gray, Habib Rahbar, Christopher Comstock, Judy A. Tjoe, Sunil Badve +5 more

Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2464

N/A

0DataRank · unranked

9 citations

Daniel L. Flynn, Cynthia B. Leary, Sun Young Oh, Xiaonan Xue, Maja H. Oktay +3 more

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2137

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07439-y

N/A

0DataRank · unranked

5 citations

Rima Patel, Emily J. Gallagher, Tianxiang Sheng, Damodara Rao Mendu, Amy Tiersten +7 more

Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells

Immunity(2025)10.1016/j.immuni.2025.07.008

N/A

0DataRank · unranked

8 citations

Kenta Nishitani, Nicole Couturier, Piril Erler, Zheng Zhang, Anna Maria Militello +14 more

Ambient air pollution and mortality in older patients with breast cancer

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf217

N/A

0DataRank · unranked

6 citations

Edgar Castro, Kanhua Yin, Min Zhang, H Thompson, Brent A. Coull +5 more

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.08.002

N/A

0DataRank · unranked

5 citations

Jincong Q. Freeman, Sri G. Yarlagadda, Aishwarya Atmakuri, Kevin Kalinsky, Lajos Pusztai +5 more

Salvage Therapy for Isolated Local-Regional Breast Cancer Recurrence

International Journal of Radiation Oncology*Biology*Physics(2025)10.1016/j.ijrobp.2025.05.077

N/A

0DataRank · unranked

4 citations

Danielle Rodin, Rima Patel, Joseph A. Sparano, Atif J. Khan, Naamit K. Gerber +1 more

Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer

Cancer Discovery(2025)10.1158/2159-8290.cd-23-0543

N/A

0DataRank · unranked

5 citations

Anna Reva, David G. Edwards, Bree M. Lege, Laura Muñoz-Arcos, Carolina Reduzzi +22 more

Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis

Cancer(2025)10.1002/cncr.35771

N/A

0DataRank · unranked

3 citations

Tianxiang Sheng, Márcio A. Diniz, Joseph A. Sparano, Amy Tiersten, Rima Patel

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

npj Breast Cancer(2020)10.1038/s41523-020-0156-0

N/A

0DataRank · unranked

208 citations

Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen +95 more

CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHL

Scientific Reports(2025)10.1038/s41598-025-11128-1

N/A

0DataRank · unranked

1 citations

Shelly Lensing, Di Chang, Larry Magpantay, Yu Guo, Ronald T. Mitsuyasu +5 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0DataRank · unranked

115 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

The Oncologist(2020)10.1634/theoncologist.2020-0039

N/A

0DataRank · unranked

14 citations

Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrózek +23 more

Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM: A Prognostic Biomarker for Metastasis

Cancers(2020)10.3390/cancers12040846

N/A

0DataRank · unranked

10 citations

Maja H. Oktay, Timothy M. D’Alfonso, Paula S. Ginter, Brian D. Robinson, Xiaonan Xue +5 more

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00968

N/A

0DataRank · unranked

27 citations

Robyn D. Gartrell, Margueritta El Asmar, Shuobo Boboila, Thomas D. Hart, Yan Lu +13 more

Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04030-2

N/A

0DataRank · unranked

24 citations

Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman +6 more

A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi’s sarcoma: AIDS Malignancy Consortium trial 059

UNC Libraries(2020)10.17615/q862-w217

N/A

0DataRank · unranked

1 citations

Anil Tulpule, Bruce J. Dezube, Dirk P. Dittmer, Rachel Bender Ignacio, Veenadhari Chavakula +13 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95

N/A

0DataRank · unranked

1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19136

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +9 more

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19132

N/A

0DataRank · unranked

3 citations

John Devin Peipert, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +15 more